Performance indicators of the medicines used in squamous cell lung cancer

Introduction. Squamous cell lung cancer is a type of non-small cell lung cancer and is specific in its clinical and pathological characteristics, the treatment process is somewhat difficult due to such reasons as old age, the presence of concomitant diseases, the location of the main tumor focuses in the center of the lung.

Objective: Determination of the effectiveness of medicines used in the treatment of lung cancer, by intellectual analysis methods.

Material and methods. The study used artificial intelligence analysis methods to process statistical data on drug consumption.

Results. According to the results of the evaluation of the effectiveness of medicines used in squamous cell lung cancer, it was revealed that such medicines as: Cisplatin ebeve® (50 mg/100 ml), Carboplatin-ebeve® (150 mg/15 ml), Carboplatin-ebeve® (450 mg/45 ml), are highly effective; Gemcitabine Ebeve® (200 mg/5 ml), Gemcitabine Ebeve® (1000 mg/25 ml), Etoposide ebeve® (100 mg/5 ml), Paclitaxel ebeve® (30 mg/5 ml), Paclitaxel ebeve® (100 mg/16,7 ml), Paclitaxel ebeve® (300 mg/50 ml), Docetaxel Ebeve ® (10 mg/ml), Docetaxel Ebeve® (20 mg/2 ml), Docetaxel Ebeve® (80 mg/8 ml), Avastin® (100 mg/4 ml), Avastin® (400 mg/16 ml), Erlonib (25 mg, No. 30), Erlonib (100 mg, No. 30), Erlonib (150 mg, No. 30), Erlonix (100 mg, No.30), Erlonix (150 mg, No. 30), Ertinob (100 mg, No. 30) Ertinob (150 mg, No. 30).

Conclusion. Based on the performance indicators of medicines used in squamous cell lung cancer, priority groups of them have been identified for admission.